Literature DB >> 11207429

Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum.

L Caberlotto1, K Fuxe, Y L Hurd.   

Abstract

Neuropeptide Y (NPY) is one of the most abundant peptides in the central nervous system. Its effects on, for example, cognition, memory and motor functions are thought to be mediated mainly via its interactions with the NPY Y1 and Y2 receptor subtypes. We had previously described the neuroanatomical organization of the Y1 and Y2 mRNA expression in humans. However, in view of the lack of information regarding the overall detailed distribution of NPY mRNA expression in the human brain, a complete picture of the anatomical organization of the NPY-related genes was still missing. Thus, in the present study, the regional distribution of NPY mRNA-expressing cells was analyzed in the post-mortem human brain. In addition, double labeling in situ hybridization was performed to characterize the NPY neuronal populations in relation to the Y1 and/or Y2 receptor mRNA localization in the human cerebral cortex, striatum, and amygdala. NPY mRNA was found to be abundant in layers II and VI of the neocortex, polymorphic layer of the dentate gyrus, basal ganglia, and amygdala. Double labeling in situ hybridization showed the co-expression of NPY mRNA with the Y2, but not with the Y1, mRNA in the human cerebral cortex, hippocampus, amygdala, striatum, and nucleus accumbens, and the existence of co-expression of the Y1 and Y2 mRNAs in the cerebral cortex and amygdala. Overall, these results suggest a role for the Y2, but not Y1, as an autoreceptor in the NPY neuronal populations of the human brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11207429     DOI: 10.1016/s0891-0618(00)00107-1

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  14 in total

1.  The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression.

Authors:  Ramon O Tasan; Ngoc Khoi Nguyen; Stefan Weger; Simone B Sartori; Nicolas Singewald; Regine Heilbronn; Herbert Herzog; Günther Sperk
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

2.  Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype.

Authors:  Cigdem Aydin; Ozge Oztan; Ceylan Isgor
Journal:  Behav Brain Res       Date:  2011-04-08       Impact factor: 3.332

Review 3.  Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y.

Authors:  Mallory E Bowers; Dennis C Choi; Kerry J Ressler
Journal:  Physiol Behav       Date:  2012-03-10

4.  Effects of isoflurane exposure during pregnancy on postnatal memory and learning in offspring rats.

Authors:  Fei-Juan Kong; Yu-Wen Tang; Ai-Fei Lou; Hong Chen; Lin-Hao Xu; Xiao-Ming Zhang; Hui-Shun Lu
Journal:  Mol Biol Rep       Date:  2011-09-25       Impact factor: 2.316

Review 5.  Neuropeptide Y and posttraumatic stress disorder.

Authors:  R Sah; T D Geracioti
Journal:  Mol Psychiatry       Date:  2012-07-17       Impact factor: 15.992

6.  Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum.

Authors:  Nathalie Thiriet; Xiaolin Deng; Marcello Solinas; Bruce Ladenheim; Wendy Curtis; Steven R Goldberg; Richard D Palmiter; Jean Lud Cadet
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

7.  In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor.

Authors:  James R Shoblock; Natalie Welty; Diane Nepomuceno; Brian Lord; Leah Aluisio; Ian Fraser; S Timothy Motley; Steve W Sutton; Kirsten Morton; Ruggero Galici; John R Atack; Lisa Dvorak; Devin M Swanson; Nicholas I Carruthers; Curt Dvorak; Timothy W Lovenberg; Pascal Bonaventure
Journal:  Psychopharmacology (Berl)       Date:  2009-12-02       Impact factor: 4.530

8.  Widespread receptivity to neuropeptide PDF throughout the neuronal circadian clock network of Drosophila revealed by real-time cyclic AMP imaging.

Authors:  Orie T Shafer; Dong Jo Kim; Richard Dunbar-Yaffe; Viacheslav O Nikolaev; Martin J Lohse; Paul H Taghert
Journal:  Neuron       Date:  2008-04-24       Impact factor: 17.173

9.  NPY mRNA expression in the prefrontal cortex: Selective reduction in the superficial white matter of subjects with schizoaffective disorder.

Authors:  Harvey M Morris; Rachelle E Stopczynski; David A Lewis
Journal:  Schizophr Res       Date:  2009-10-04       Impact factor: 4.939

Review 10.  Neuropeptide Y: A stressful review.

Authors:  Florian Reichmann; Peter Holzer
Journal:  Neuropeptides       Date:  2015-09-30       Impact factor: 3.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.